Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...

Gensaic partnership with Novo Nordisk, worth up to $354M, aims to develop next-generation precision therapies using novel protein design technology.

A national survey conducted by MedStar Health to gauge the public's knowledge of screening guidelines for colorectal cancer, ...

RevSpring, the leading provider of healthcare engagement and payment solutions, today announced Let's Talktm?an always-available virtual agent that seamlessly handles inbound calls from ...